237 related articles for article (PubMed ID: 14870957)
1. Chronic cannabis abuse raises nerve growth factor serum concentrations in drug-naive schizophrenic patients.
Jockers-Scherübl MC; Matthies U; Danker-Hopfe H; Lang UE; Mahlberg R; Hellweg R
J Psychopharmacol; 2003 Dec; 17(4):439-45. PubMed ID: 14870957
[TBL] [Abstract][Full Text] [Related]
2. Adequate antipsychotic treatment normalizes serum nerve growth factor concentrations in schizophrenia with and without cannabis or additional substance abuse.
Jockers-Scherübl MC; Rentzsch J; Danker-Hopfe H; Radzei N; Schürer F; Bahri S; Hellweg R
Neurosci Lett; 2006 Jun; 400(3):262-6. PubMed ID: 16540246
[TBL] [Abstract][Full Text] [Related]
3. Brain-derived neurotrophic factor serum concentrations are increased in drug-naive schizophrenic patients with chronic cannabis abuse and multiple substance abuse.
Jockers-Scherübl MC; Danker-Hopfe H; Mahlberg R; Selig F; Rentzsch J; Schürer F; Lang UE; Hellweg R
Neurosci Lett; 2004 Nov; 371(1):79-83. PubMed ID: 15500971
[TBL] [Abstract][Full Text] [Related]
4. [Schizophrenia and cannabis consumption: epidemiology and clinical symptoms].
Jockers-Scherübl MC
Prax Kinderpsychol Kinderpsychiatr; 2006; 55(7):533-43. PubMed ID: 17058779
[TBL] [Abstract][Full Text] [Related]
5. Reduced serum concentrations of nerve growth factor, but not brain-derived neurotrophic factor, in chronic cannabis abusers.
Angelucci F; Ricci V; Spalletta G; Pomponi M; Tonioni F; Caltagirone C; Bria P
Eur Neuropsychopharmacol; 2008 Dec; 18(12):882-7. PubMed ID: 18774699
[TBL] [Abstract][Full Text] [Related]
6. Reduced NGF serum levels and abnormal P300 event-related potential in first episode schizophrenia.
Xiong P; Zeng Y; Zhu Z; Tan D; Xu F; Lu J; Wan J; Ma M
Schizophr Res; 2010 Jun; 119(1-3):34-9. PubMed ID: 20303241
[TBL] [Abstract][Full Text] [Related]
7. Differential impact of heavy cannabis use on sensory gating in schizophrenic patients and otherwise healthy controls.
Rentzsch J; Penzhorn A; Kernbichler K; Plöckl D; Gómez-Carrillo de Castro A; Gallinat J; Jockers-Scherübl MC
Exp Neurol; 2007 May; 205(1):241-9. PubMed ID: 17368620
[TBL] [Abstract][Full Text] [Related]
8. Cannabis induces different cognitive changes in schizophrenic patients and in healthy controls.
Jockers-Scherübl MC; Wolf T; Radzei N; Schlattmann P; Rentzsch J; Gómez-Carrillo de Castro A; Kühl KP
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1054-63. PubMed ID: 17482741
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of chronic cannabis use on preattentional cognitive functioning in abstinent schizophrenic patients and healthy subjects.
Rentzsch J; Buntebart E; Stadelmeier A; Gallinat J; Jockers-Scherübl MC
Schizophr Res; 2011 Aug; 130(1-3):222-7. PubMed ID: 21624823
[TBL] [Abstract][Full Text] [Related]
10. The role of NGF and IL-2 serum level in assisting the diagnosis in first episode schizophrenia.
Xiong P; Zeng Y; Wan J; Xiaohan DH; Tan D; Lu J; Xu F; Li HY; Zhu Z; Ma M
Psychiatry Res; 2011 Aug; 189(1):72-6. PubMed ID: 21277636
[TBL] [Abstract][Full Text] [Related]
11. Nerve growth factor and brain-derived neurotrophic factor concentrations in schizophrenia: a review.
Martinotti G; Di Iorio G; Marini S; Ricci V; De Berardis D; Di Giannantonio M
J Biol Regul Homeost Agents; 2012; 26(3):347-56. PubMed ID: 23034254
[TBL] [Abstract][Full Text] [Related]
12. Cannabis and schizophrenia: impact on onset, course, psychopathology and outcomes.
Bersani G; Orlandi V; Kotzalidis GD; Pancheri P
Eur Arch Psychiatry Clin Neurosci; 2002 Apr; 252(2):86-92. PubMed ID: 12111342
[TBL] [Abstract][Full Text] [Related]
13. Cannabis, vulnerability, and the onset of schizophrenia: an epidemiological perspective.
Hambrecht M; Häfner H
Aust N Z J Psychiatry; 2000 Jun; 34(3):468-75. PubMed ID: 10881971
[TBL] [Abstract][Full Text] [Related]
14. Cannabis abuse is associated with decision-making impairment among first-episode patients with schizophrenia-spectrum psychosis.
Mata I; Rodríguez-Sánchez JM; Pelayo-Terán JM; Pérez-Iglesias R; González-Blanch C; Ramírez-Bonilla M; Martínez-García O; Vázquez-Barquero JL; Crespo-Facorro B
Psychol Med; 2008 Sep; 38(9):1257-66. PubMed ID: 18005495
[TBL] [Abstract][Full Text] [Related]
15. Neuregulin-1 is increased in schizophrenia patients with chronic cannabis abuse: Preliminary results.
Aukst Margetic B; Peitl V; Vukasović I; Karlović D
Schizophr Res; 2019 Jun; 208():473-474. PubMed ID: 30799217
[No Abstract] [Full Text] [Related]
16. Changes in serum levels of brain derived neurotrophic factor and nerve growth factor-beta in schizophrenic patients before and after treatment.
Ajami A; Hosseini SH; Taghipour M; Khalilian A
Scand J Immunol; 2014 Jul; 80(1):36-42. PubMed ID: 24498860
[TBL] [Abstract][Full Text] [Related]
17. Cannabis and brain morphology in recent-onset schizophrenia.
Cahn W; Hulshoff Pol HE; Caspers E; van Haren NE; Schnack HG; Kahn RS
Schizophr Res; 2004 Apr; 67(2-3):305-7. PubMed ID: 14984893
[No Abstract] [Full Text] [Related]
18. [Comparative study of substance dependence comorbidity in bipolar, schizophrenic and schizoaffective disorders].
Verdoux H; Mury M; Besançon G; Bourgeois M
Encephale; 1996; 22(2):95-101. PubMed ID: 8706627
[TBL] [Abstract][Full Text] [Related]
19. Schizophrenia in users and nonusers of cannabis. A longitudinal study in Stockholm County.
Andréasson S; Allebeck P; Rydberg U
Acta Psychiatr Scand; 1989 May; 79(5):505-10. PubMed ID: 2787581
[TBL] [Abstract][Full Text] [Related]
20. Craving in patients with schizophrenia and cannabis use disorders.
Schnell T; Becker T; Thiel MC; Gouzoulis-Mayfrank E
Can J Psychiatry; 2013 Nov; 58(11):646-9. PubMed ID: 24246436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
